AcouSort (ACOU) Q4 2024 earnings summary

Executive summary

• Focused on expanding OEM partnerships, especially in cell therapy and flow cytometry, with five new collaborations in 2024 and increased global presence at key industry events.

• Launched first clinical system based on AcouSort technology and saw Werfen launch a point-of-care system using AcouSort’s acoustofluidics.

• Secured SEK 4.5 million in loan guarantees, ensuring working capital into Q3 2025.

Financial highlights

• Q4 net sales: TSEK 1,221 (0); full-year net sales: TSEK 4,737 (5,534), reflecting a decrease year-over-year.

• Q4 result before tax: TSEK -2,829 (-6,554); full-year result before tax: TSEK -15,078 (-17,089), showing reduced losses.

• Q4 result per share: SEK -0.19 (-0.49); full-year: SEK -1.01 (-1.29).

• Cash and cash equivalents at year-end: TSEK 3,568 (23,986); equity ratio: 69% (70%).

• Total income for 2024: SEK 10.0 million (10.6); royalty income: SEK 3.5 million, expected to reach at least SEK 5.25 million in 2025.

Outlook and guidance

• Board confident that current cash, future revenues, and loan guarantees will fund operations into Q3 2025.

• Focus for 2025 on strengthening positions in cell therapy, flow cytometry, and quality control through ongoing and new partnerships.

• Royalty income expected to increase to at least SEK 5.25 million in 2025.